CareDx Reports Second Quarter 2023 Results

CareDx, Inc. – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – reported financial results for the second quarter ended June 30, 2023.

BRISBANE, Calif.--(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported financial results for the second quarter ended June 30, 2023.

Second Quarter 2023 Highlights and Other Recent Updates

  • CareDx received the industry’s first and only multimodal MolDX approval in transplant with HeartCare for Medicare patients.
  • CareDx received the industry’s first and only donor-derived cell-free DNA (dd-cfDNA) MolDX approval for lung transplant patients with AlloSure® Lung for Medicare patients.
  • Reported revenue of $70.3 million, a decrease of 13% year-over-year due to the impact of the Medicare Billing Article revisions.
  • Reported testing services revenue of $53.4 million, a decrease of 20% year-over-year. Achieved growth in non-testing services business with revenues of $9.0 million for Patient and Digital Solutions and $7.9 million for Products, representing year-over-year growth of 33% and 17% respectively.
  • Achieved over 80% adoption of new test requisition forms (TRFs) by the end of June, two quarters ahead of target.
  • Delivered approximately 37,500 patient test results for AlloMap® and AlloSure, a decline of approximately 17% year-over-year, driven by the impact of the Medicare Billing Article revisions and operational adjustments required of customers.
  • Collected over $20.0 million in incremental cash, driven by cash collections at 110% of revenue for testing services in the last three quarters.
  • Maintained strong balance sheet with $283 million of cash and cash equivalents, and marketable securities, with no debt.

“We are proud to continue our transplant innovation leadership, as the first and only company to receive Medicare coverage for multimodality in transplantation with HeartCare, and dd-cfDNA in lung with AlloSure Lung,” said Reg Seeto, CEO and President of CareDx. “A key focus for the second quarter was operational execution of the Billing Article revisions and we are pleased to achieve over 80 percent adoption rate for our new TRFs, well ahead of target.”

Second Quarter 2023 Financial Results

Revenue for the three months ended June 30, 2023, was $70.3 million, a decrease of 13% compared with $80.6 million in the second quarter of 2022. Testing services revenue for the quarter was $53.4 million, compared with $67.1 million in the same period in 2022. This includes approximately $7.8 million in revenue associated with AlloSure Kidney Medicare tests that the company did not submit for reimbursement in the first quarter of 2023.

Total AlloSure and AlloMap patient results provided in the quarter were approximately 37,500, representing a decrease of approximately 17% as compared to the same quarter a year ago, and primarily attributable to the impact of the Medicare Billing Article revisions on AlloSure Kidney testing volumes.

For the second quarter of 2023, net loss was $25.0 million, compared to a net loss of $21.7 million in the same period in 2022. Basic and diluted net loss per share in the second quarter of 2023 was $0.46, compared to basic and diluted net loss per share of $0.41 in the second quarter of 2022.

Non-GAAP net loss was $9.9 million in the second quarter of 2023, compared to a non-GAAP net loss of $7.0 million in the second quarter of 2022. Basic and diluted non-GAAP net loss per share was $0.18 in the second quarter of 2023, compared to a basic and diluted non-GAAP net loss per share of $0.13 in the second quarter of 2022.

Adjusted EBITDA for the second quarter of 2023 was a loss of $10.4 million, compared to an adjusted EBITDA loss of $5.7 million in the second quarter of 2022.

Cash and cash equivalents and marketable securities were $283 million as of June 30, 2023.

2023 Guidance

For the full year 2023, CareDx expects revenue to be in the range of $240 to $260 million.

About CareDx – The Transplant Company™

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

Forward Looking Statements

This press release includes forward-looking statements with respect to expectations regarding its 2023 revenue. All statements other than statements of historical fact contained in this press release, including statements regarding the future financial position of CareDx, including financial targets, business strategy and plans and objectives for future operations, are forward-looking statements. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, all of which are difficult to predict and many of which are beyond our control, including general economic and market factors, and global economic and marketplace uncertainties, among others discussed in CareDx’s filings with the Securities and Exchange Commission (the “SEC”), including but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed by CareDx with the SEC on February 27, 2023, the quarterly report on Form 10-Q for the quarter ended March 31, 2023 filed by CareDx with the SEC on May 10, 2023, and the quarterly report on Form 10-Q for the quarter ended June 30, 2023 to be filed by CareDx with the SEC on or about August 8, 2023, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Use of Non-GAAP Financial Measures

CareDx has presented in this release certain financial information in accordance with U.S. Generally Accepted Accounting Principles (GAAP) and also on a non-GAAP basis, including non-GAAP cost of testing services, non-GAAP cost of product, non-GAAP cost of patient and digital solutions, non-GAAP research and development expenses, non-GAAP sales and marketing expenses, non-GAAP general and administrative expenses, non-GAAP other income (expense), net, non-GAAP income tax expense, non-GAAP gross profit, non-GAAP gross margin (%), non-GAAP net loss, non-GAAP basic and diluted net loss per share, adjusted EBITDA, adjusted revenue from testing services, and adjusted total revenue. We define non-GAAP net loss and per share results as the GAAP net loss and per share results excluding the impacts of stock-based compensation; changes in estimated fair value of contingent consideration; acquisition-related impairment charges and amortization of purchased intangible assets and related tax effects; costs involved with completing an acquisition; unrealized loss on investments; restructuring charges and certain other charges. We define adjusted EBITDA as non-GAAP net loss before net interest income, income tax benefit, depreciation and other expense, net. This release also contains adjusted revenue from testing services, which was prepared on a non-GAAP basis that excludes the $7.8 million revenue associated with the recognized AlloSure Kidney Medicare claims. We are presenting these non-GAAP financial measures to assist investors in assessing our operating results through the eyes of management and because we believe that these measures provide an additional tool for investors to use in comparing our core business operating results over multiple periods. Management believes this non-GAAP information is useful for investors, when considered in conjunction with CareDx’s GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of CareDx’s operating results as reported under GAAP. These non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. These non-GAAP financial measures are not necessarily comparable to similarly-titled measures presented by other companies. A reconciliation between GAAP and non-GAAP financial information is provided immediately following the financial tables.

CareDx, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

(In thousands, except share and per share data)

Three Months Ended June 30,

Six Months Ended June 30,

2023

2022

2023

2022

Revenue:

Testing services revenue

$

53,414

$

67,135

$

115,198

$

133,579

Product revenue

7,876

6,714

14,737

13,502

Patient and digital solutions revenue

9,011

6,785

17,628

12,969

Total revenue

70,301

80,634

147,563

160,050

Operating expenses:

Cost of testing services

15,324

18,230

30,620

35,858

Cost of product

3,926

3,887

7,992

8,286

Cost of patient and digital solutions

6,637

5,422

13,241

10,277

Research and development

20,233

22,632

44,590

44,512

Sales and marketing

21,630

26,950

44,861

50,098

General and administrative

29,327

25,232

57,359

51,791

Restructuring costs

848

848

Total operating expenses

97,925

102,353

199,511

200,822

Loss from operations

(27,624

)

(21,719

)

(51,948

)

(40,772

)

Other income (expense):

Interest income, net

2,871

478

5,537

667

Change in estimated fair value of common stock warrant liability

3

48

10

75

Other expense, net

(271

)

(553

)

(2,245

)

(1,376

)

Total other income (expense)

2,603

(27

)

3,302

(634

)

Loss before income taxes

(25,021

)

(21,746

)

(48,646

)

(41,406

)

Income tax benefit (expense)

68

49

(56

)

61

Net loss

$

(24,953

)

$

(21,697

)

$

(48,702

)

$

(41,345

)

Net loss per share:

Basic

$

(0.46

)

$

(0.41

)

$

(0.91

)

$

(0.78

)

Diluted

$

(0.46

)

$

(0.41

)

$

(0.91

)

$

(0.78

)

Weighted-average shares used to compute net loss per share:

Basic

53,846,260

53,249,545

53,745,299

53,133,149

Diluted

53,846,260

53,249,545

53,745,299

53,133,149

CareDx, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands)

June 30, 2023

December 31, 2022

Assets

Current assets:

Cash and cash equivalents

$

87,786

$

89,921

Marketable securities

194,887

203,168

Accounts receivable

51,625

66,312

Inventory

18,840

19,232

Prepaid and other current assets

7,676

9,216

Total current assets

360,814

387,849

Property and equipment, net

36,084

35,529

Operating leases right-of-use assets

32,118

34,689

Intangible assets, net

43,529

43,051

Goodwill

39,655

37,523

Restricted cash

584

522

Other assets

2,036

3,828

Total assets

$

514,820

$

542,991

Liabilities and stockholders’ equity

Current liabilities:

Accounts payable

$

9,880

$

9,942

Accrued compensation

14,441

16,902

Accrued and other liabilities

50,175

49,131

Total current liabilities

74,496

75,975

Deferred tax liability

51

Common stock warrant liability

32

Deferred payments for intangible assets

4,224

2,418

Operating lease liability, less current portion

30,589

33,406

Other liabilities

247

249

Total liabilities

109,607

112,080

Commitments and contingencies

Stockholders’ equity:

Common stock

52

52

Additional paid-in capital

923,514

898,806

Accumulated other comprehensive loss

(8,450

)

(7,503

)

Accumulated deficit

(509,903

)

(460,444

)

Total stockholders’ equity

405,213

430,911

Total liabilities and stockholders’ equity

$

514,820

$

542,991

CareDx, Inc.

Reconciliation of GAAP to Non-GAAP Financial Measures

(Unaudited)

(In thousands)

Three Months Ended June 30,

Six Months Ended June 30,

2023

2022

2023

2022

Cost of testing services reconciliation:

GAAP cost of testing services

$

15,324

$

18,230

$

30,620

$

35,858

Stock-based compensation expense

(492

)

(566

)

(971

)

(585

)

Acquisition related-amortization of purchased intangibles

(329

)

(329

)

(658

)

(658

)

Non-GAAP cost of testing services

$

14,503

$

17,335

$

28,991

$

34,615

Cost of product reconciliation:

GAAP cost of product

$

3,926

$

3,887

$

7,992

$

8,286

Stock-based compensation expense

(274

)

(402

)

(634

)

(530

)

Acquisition related-amortization of purchased intangibles

(416

)

(437

)

(834

)

(890

)

Non-GAAP cost of product

$

3,236

$

3,048

$

6,524

$

6,866

Cost of patient and digital solutions reconciliation:

GAAP cost of patient and digital solutions

$

6,651

$

5,422

$

13,255

$

10,277

Stock-based compensation expense

(367

)

(391

)

(769

)

(583

)

Acquisition related-amortization of purchased intangibles

(255

)

(236

)

(503

)

(472

)

Restructuring costs

(14

)

(14

)

Non-GAAP cost of patient and digital solutions

$

6,015

$

4,795

$

11,969

$

9,222

Research and development expenses reconciliation:

GAAP research and development expenses

$

20,478

$

22,632

$

44,835

$

44,512

Stock-based compensation expense

(1,704

)

(2,323

)

(3,666

)

(4,513

)

Restructuring costs

(245

)

(245

)

Non-GAAP research and development expenses

$

18,529

$

20,309

$

40,924

$

39,999

Sales and marketing expenses reconciliation:

GAAP sales and marketing expenses

$

22,178

$

26,950

$

45,409

$

50,098

Stock-based compensation expense

(2,779

)

(3,907

)

(6,516

)

(7,030

)

Acquisition related-amortization of purchased intangibles

(606

)

(543

)

(1,201

)

(1,148

)

Restructuring costs

(548

)

(548

)

Non-GAAP sales and marketing expenses

$

18,245

$

22,500

$

37,144

$

41,920

General and administrative expenses reconciliation:

GAAP general and administrative expenses

$

29,368

$

25,232

$

57,400

$

51,791

Stock-based compensation expense

(7,084

)

(5,004

)

(13,898

)

(9,986

)

Change in estimated fair value of contingent consideration

(67

)

(500

)

(488

)

(564

)

Acquisition related fees and expenses

(186

)

(284

)

(329

)

Restructuring costs and charges

(41

)

(99

)

Non-GAAP general and administrative expenses

$

22,176

$

19,542

$

42,631

$

40,912

Total other income (expense) reconciliation:

GAAP other income (expense), net

$

2,603

$

(27

)

$

3,302

$

(634

)

Unrealized (gain) loss on long-term marketable equity securities

(53

)

(21

)

857

486

Asset impairments and write-downs

1,000

Other charges (income)

7

(11

)

28

17

Non-GAAP other income (expense), net

$

2,557

$

(59

)

$

5,187

$

(131

)

Income tax benefit (expense) reconciliation:

GAAP income tax benefit (expense)

$

68

$

49

$

(56

)

$

61

Tax effect related to amortization of purchased intangibles

(100

)

(107

)

(201

)

(220

)

Non-GAAP income tax expense

$

(32

)

$

(58

)

$

(257

)

$

(159

)

CareDx, Inc.

Reconciliation of GAAP to Non-GAAP Gross Profit and Gross Margin

(Unaudited)

(In thousands, except percentages)

Three Months Ended June 30,

Six Months Ended June 30,

2023

2022

2023

2022

Total revenue

$

70,301

$

80,634

$

147,563

$

160,050

GAAP cost of sales

25,901

27,539

51,867

54,421

GAAP gross profit

44,400

53,095

95,696

105,629

Stock-based compensation expense

1,133

1,359

2,374

1,698

Restructuring costs

14

14

Acquisition related-amortization of purchased intangibles

1,000

1,002

1,995

2,020

Non-GAAP gross profit

$

46,547

$

55,456

$

100,079

$

109,347

Non-GAAP gross margin %

66

%

69

%

68

%

68

%

CareDx, Inc.

Reconciliation of GAAP to Non-GAAP Financial Measures

(Unaudited)

(In thousands, except share and per share data)

Three Months Ended June 30,

Six Months Ended June 30,

2023

2022

2023

2022

GAAP net loss

$

(24,953

)

$

(21,697

)

$

(48,702

)

$

(41,345

)

Stock-based compensation expense

12,700

12,593

26,454

23,227

Asset impairments and write-downs

1,000

Unrealized (gain) loss on long-term marketable equity securities

(53

)

(21

)

857

486

Acquisition related-amortization of purchased intangibles

1,606

1,545

3,196

3,168

Acquisition related fees and expenses

186

284

329

Change in estimated fair value of contingent consideration

67

500

488

564

Restructuring costs and charges

848

906

Tax effect related to amortization of purchased intangibles

(100

)

(107

)

(201

)

(220

)

Other charges (income)

7

(11

)

28

17

Non-GAAP net loss

$

(9,878

)

$

(7,012

)

$

(15,690

)

$

(13,774

)

GAAP basic and diluted net loss per share

$

(0.46

)

$

(0.41

)

$

(0.91

)

$

(0.78

)

Non-GAAP basic net loss per share

$

(0.18

)

$

(0.13

)

$

(0.29

)

$

(0.26

)

Non-GAAP diluted net loss per share

$

(0.18

)

$

(0.13

)

$

(0.29

)

$

(0.26

)

Shares used in computing non-GAAP basic net loss per share

53,846,260

53,249,545

53,745,299

53,133,149

Shares used in computing non-GAAP diluted net loss per share

53,846,260

53,249,545

53,745,299

53,133,149

CareDx, Inc.

Reconciliation of Non-GAAP to Adjusted EBITDA

(Unaudited)

(In thousands)

Three Months Ended June 30,

Six Months Ended June 30,

2023

2022

2023

2022

Non-GAAP net loss

$

(9,878

)

$

(7,012

)

$

(15,690

)

$

(13,774

)

Interest income

(2,871

)

(478

)

(5,537

)

(667

)

Income tax benefit (expense)

68

58

(56

)

159

Depreciation expense

2,052

1,162

3,860

2,102

Other expense, net

279

537

664

798

Adjusted EBITDA

$

(10,350

)

$

(5,733

)

$

(16,759

)

$

(11,382

)

CareDx, Inc.

Reconciliation of GAAP Revenue to Adjusted Revenue

(Unaudited)

(In thousands)

Three Months Ended June 30, 2023

Testing Services

Total Revenue

GAAP revenue

$

53,414

$

70,301

Recognized AlloSure Kidney Medicare claims

(7,771

)

(7,771

)

Total adjusted revenue

$

45,643

$

62,530

View source version on businesswire.com: https://www.businesswire.com/news/home/20230808569298/en/

Contacts

CareDx, Inc.

Media Relations
Anna Czene
818-731-2203
aczene@caredx.com

Investor Relations
Greg Chodaczek
investor@caredx.com

Source: CareDx, Inc.

MORE ON THIS TOPIC